Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies
Open Access
- 16 June 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e047462
Abstract
Once considered rare and essentially untreatable with a grim prognosis and reduced life expectancy, hypertrophic cardiomyopathy (HCM) has evolved substantially over 6 decades. Ultimately, HCM has become a contemporary global disease with pharmacologic and interventional options offering effective personalized treatment for all adverse disease pathways. Striking reduction in HCM‐related mortality to ≤0.5%/year in optimally treated cohorts is now comparable to that expected in the US general population, lower than most other disease risks to living, and 10‐fold less than the earliest estimates. The few deaths directly related to HCM are now largely attributable to advanced (end‐stage) heart failure in patients with nonobstructive HCM. Determinants of this transformation to a lower risk disease are evident in hallmark clinical inflection points and breakthroughs, including dedicated HCM programs assembling large clinical databases in which focused (and unfunded) physician‐investigators have derived data directly from patients in clinical practice. Evidence‐based observational studies report emergence of contemporary treatment strategies enhancing survival: implantable defibrillators prevent arrhythmic sudden death globally with 95% sensitive patient selection using an American Heart Association/American College Cardiology risk stratification algorithm; low‐risk, high‐benefit surgical myectomy reverses outflow obstruction and heart failure in >90% with a long‐term survival benefit; and aggressive anticoagulation has reduced embolic strokes. Recent novel pharmacologic alternatives (cardiac myosin inhibitors) are proving effective in relieving obstruction/symptom burden and changing disease management. These principles and time‐tested patient‐centered research strategies uniquely tailored to the heterogeneous HCM clinical spectrum are pivotal in providing practice insights, offering a vulnerable population more optimistic prognosis including opportunity to achieve normal longevity not available to prior generations of patients.Keywords
This publication has 106 references indexed in Scilit:
- Annual Report to the Nation on the Status of Cancer, featuring state‐level statistics after the onset of the COVID‐19 pandemicCancer, 2025
- Myocardial Scarring and Sudden Cardiac Death in Young Patients With Hypertrophic CardiomyopathyJAMA Cardiology, 2024
- Sickle Cell Disease Approvals Include First CRISPR Gene Editing TherapyJAMA, 2024
- Emulation of Randomized Clinical Trials With Nonrandomized Database AnalysesJAMA, 2023
- Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European PopulationJAMA Cardiology, 2020
- Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic CardiomyopathyJAMA Cardiology, 2019
- Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic EventsJAMA Cardiology, 2018
- Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic CardiomyopathyJAMA, 2007
- Clinical Course of Hypertrophic Cardiomyopathy in a Regional United States CohortJAMA, 1999
- Hypertrophie cardiomyopathy: A discussion of nomenclatureThe American Journal of Cardiology, 1979